Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board

About this update from Dogwood Therapeutics, Inc.

Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026 ALPHARETTA, Ga., June 30, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) ("Dogwood" or the "Company"), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced the appointment of veteran biopharma industry executive and OrbiMed partner, Iain Dukes, Ph.D., as Chair of the Company's newly formed Scientific Advisory Board ("SAB"). As Chair of the SAB, Dr. Dukes will advise the Company's leadership team and Board on scientific developments for the Company's pipeline of novel therapeutics for pain and neuropathy. Dogwood is currently advancing Halneuron® in chemotherapy-induced neuropathic pain ("CINP"), with Phase 2b data anticipated in the fall of 2026, and SP16 in chemotherapy-induced peripheral neuropathy ("CIPN"), which has received FDA clearance to progress into Phase 1b development. "Iain is widely recognized throughout the biopharma industry as a successful scientist, investor and business leader, and we are delighted to welcome him as Chair of our newly formed SAB," said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. "Dr. Dukes has deep experience in the field of ion channel therapeutics development, and this experience is directly relevant to our ongoing development of Halneuron, a NaV 1.7 sodium channel inhibitor. We look forward to his guidance and expertise as we further expand our SAB and advance our pipeline of novel therapeutics for pain and neuropathy." Dr. Dukes is a Venture Partner at OrbiMed Advisors LLC. He previously served as Senior Vice President and Head of Business Development and Licensing for Merck Research Laboratories. Prior to joining Merck, Dr. Dukes was Vice President of External Research and Development at Amgen. He has also served as President and Chief Executive Officer, as well as a member of the Board of Directors of Essentialis Therapeutics, a clinical stage biotechnology company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases. Previously, Dr. Dukes was Vice President of Scientific and Technology Licensing at GlaxoSmithKline, and he held various positions at Glaxo Wellcome, including Head of Exploratory Deve...

View stock analysis, news, and events for Dogwood Therapeutics, Inc.